STOCK TITAN

Structure Therapeutics Inc. American Depositary Shares - GPCR STOCK NEWS

Welcome to our dedicated page for Structure Therapeutics American Depositary Shares news (Ticker: GPCR), a resource for investors and traders seeking the latest updates and insights on Structure Therapeutics American Depositary Shares stock.

Structure Therapeutics Inc. (NASDAQ: GPCR) is a clinical-stage biopharmaceutical company revolutionizing the treatment of chronic diseases through innovative oral therapeutics. The company’s lead product candidate, GSBR-1290, is an oral small molecule agonist targeting the glucagon-like-peptide-1 receptor (GLP-1R), a proven drug target for type-2 diabetes and obesity. By focusing on GPCRs, Structure Therapeutics aims to address significant unmet medical needs in metabolic and cardiopulmonary diseases.

In recent developments, Structure Therapeutics reported promising results from its Phase 1b study of GSBR-1290, showcasing its potential as a differentiated oral GLP-1 receptor agonist. The company is advancing GSBR-1290 into Phase 2 trials, aiming to further demonstrate its efficacy and safety in treating type-2 diabetes and obesity. Additionally, the company is developing other oral small-molecule therapeutics, including ANPA-0073 and LTSE-2578, targeting pulmonary and cardiovascular diseases.

Financially, Structure Therapeutics is in a robust position, with a cash reserve of $205.4 million as of September 30, 2023, and an additional $300 million raised through private placement in October 2023. This strong financial backing will support the advancement of the company’s clinical programs and achieve key milestones through 2026.

Structure Therapeutics' commitment to scientific innovation is evident in its next-generation structure-based drug discovery platform, which underpins its GPCR-targeted pipeline. The company’s strategic partnerships with leading healthcare investors further bolster its mission to deliver transformative oral therapies to patients worldwide.

For more information, visit www.structuretx.com.

Rhea-AI Summary

Structure Therapeutics, a clinical-stage biopharmaceutical company (NASDAQ: GPCR), has filed a Form S-1 registration statement with the SEC for a proposed public offering of 8,000,000 American depositary shares (ADSs). Each ADS represents three ordinary shares. The company may also offer pre-funded warrants in lieu of ADSs. The price per pre-funded warrant will be the ADS price minus $0.0001. The underwriters have a 30-day option to purchase up to an additional 1,200,000 ADSs. The offering's completion depends on market conditions and other factors. Joint book-running managers include Goldman Sachs, Morgan Stanley, Jefferies, Leerink Partners, Guggenheim Securities, and BMO Capital Markets.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.94%
Tags
-
Rhea-AI Summary

Structure Therapeutics announced positive topline data from its Phase 2a study and capsule to tablet PK study for its oral GLP-1 receptor agonist, GSBR-1290. The Phase 2a study showed a statistically significant placebo-adjusted mean weight loss of 6.2% at 12 weeks, while the capsule to tablet PK study achieved up to a 6.9% weight loss. GSBR-1290 demonstrated favorable safety and tolerability with low discontinuation rates due to adverse events.

The company plans to start a 36-week Phase 2b study in the fourth quarter of 2024, following an IND submission to the FDA in the third quarter. The new study will use the tablet formulation and involve approximately 300 participants.

These results underscore the potential of GSBR-1290 as a treatment for obesity, with benefits including once-daily dosing and favorable safety profiles. Future development plans include exploring higher doses and combination therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
54.21%
Tags
-
Rhea-AI Summary

Structure Therapeutics Inc., a biopharmaceutical company, reported financial results for Q1 2024, highlighting upcoming milestones such as data release for obesity drug GSBR-1290 and plans for Phase 2b study. The company aims to address obesity epidemic with its oral small molecule GLP-1 receptor agonist. Positive financial highlights include a cash position of $436.4 million, funding projected operations through 2026.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-7.32%
Tags
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) CEO to participate in a fireside chat at Leerink Partners Global Biopharma Conference. The company is developing novel oral small molecule therapeutics for metabolic and cardiopulmonary diseases.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.75%
Tags
conferences
-
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) reported financial results for Q4 and full year 2023, with a year-end cash balance of $467.3 million. The company highlighted successful Phase 2a data for GSBR-1290 in obesity and type 2 diabetes, with plans for Phase 2b trials. They also outlined upcoming milestones for other programs targeting metabolic and cardiopulmonary diseases. The company raised $485.0 million in equity capital in 2023, with strong financials to fund operations through 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.36%
Tags
-
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) provided a development program update for its oral GLP-1 receptor agonist, GSBR-1290. The Phase 2a data showed significant reductions in HbA1c and weight in type 2 diabetes mellitus patients and obesity cohorts. The drug demonstrated favorable safety, tolerability, and efficacy, with no treatment-related serious adverse events and a low study discontinuation rate. The company plans to initiate a Phase 2b study in the second half of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-42.82%
Tags
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) announced positive results from the Phase 1b clinical study of oral GLP-1 receptor agonist, GSBR-1290, showing significant weight loss and an encouraging safety profile. They also highlighted upcoming milestones for GSBR-1290 in treating Type 2 Diabetes Mellitus (T2DM) and obesity, with topline data expected in December 2023 and first half of 2024, respectively. The company completed a $300 million financing, expected to fund operations through at least 2026.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.83%
Tags
-
Rhea-AI Summary
Structure Therapeutics Inc. announces a $300 million private placement financing, with significant participation from large healthcare institutional and mutual fund investors. The financing is expected to extend the company's cash runway through 2026. The proceeds will be used to accelerate the development of GSBR-1290 and other programs in the company's oral incretin franchise. Development candidates for these programs are expected to be delivered in 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.56%
Tags
none
-
Rhea-AI Summary
Structure Therapeutics Inc. announces positive results from Phase 1b study of GSBR-1290, a selective oral GLP-1 receptor agonist, in overweight or obese individuals. Significant weight loss observed, supporting once-daily dosing. Phase 2a data for type 2 diabetes cohort expected Q4 2023, obesity cohort in H1 2024. Phase 2b studies planned for 2024. No adverse event-related discontinuations. Mild gastrointestinal-related adverse events reported. No clinically meaningful changes in liver function tests.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
34.56%
Tags
Rhea-AI Summary
Structure Therapeutics Inc. (NASDAQ: GPCR) completed enrollment in a 12-week Phase 2a study of GSBR-1290, with topline data expected in the latter half of the fourth quarter 2023. The company also reported financial results for the second quarter of 2023 and highlighted recent corporate achievements, including the appointment of Dr. Ted Love to its Board of Directors. With a cash position of $224.6 million at June 30, 2023, the company expects its current cash to fund operations through expected key clinical milestones through at least 2025.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.06%
Tags

FAQ

What is the current stock price of Structure Therapeutics American Depositary Shares (GPCR)?

The current stock price of Structure Therapeutics American Depositary Shares (GPCR) is $32.71 as of November 20, 2024.

What is the market cap of Structure Therapeutics American Depositary Shares (GPCR)?

The market cap of Structure Therapeutics American Depositary Shares (GPCR) is approximately 1.9B.

What is Structure Therapeutics Inc.'s main focus?

Structure Therapeutics Inc. focuses on developing novel oral therapeutics for chronic metabolic and cardiopulmonary diseases, leveraging their structure-based drug discovery platform.

What is GSBR-1290?

GSBR-1290 is Structure Therapeutics Inc.'s lead product candidate, an oral small molecule agonist targeting the GLP-1 receptor, aimed at treating type-2 diabetes and obesity.

What recent financial achievements has Structure Therapeutics made?

Structure Therapeutics recently raised $300 million through a private placement, bolstering its financial position to support clinical development through 2026.

What are the other therapeutic candidates in the pipeline?

In addition to GSBR-1290, Structure Therapeutics is developing ANPA-0073 and LTSE-2578, targeting pulmonary and cardiovascular diseases.

How does Structure Therapeutics plan to use the proceeds from the recent financing?

The company plans to use the proceeds to accelerate the development of GSBR-1290 and advance other programs from its oral incretin franchise.

What makes Structure Therapeutics' drug discovery platform unique?

Structure Therapeutics utilizes a next-generation structure-based drug discovery platform, which targets GPCRs to develop innovative oral treatments for chronic diseases.

Who are the key partners in the recent private placement financing?

The financing includes significant participation from large healthcare-dedicated institutional and mutual fund investors.

What are the company's plans for GSBR-1290 in 2024?

Structure Therapeutics expects to deliver development candidates for GSBR-1290 and its next-generation GLP-1/GIPR combination and oral small molecule amylin receptor agonists in 2024.

How is Structure Therapeutics addressing the unmet medical needs?

By developing oral small-molecule therapeutics that target validated GPCR drug targets, Structure Therapeutics aims to provide effective treatments for conditions like type-2 diabetes, obesity, and cardiovascular diseases.

Where can I find more information about Structure Therapeutics?

For more information, you can visit the company's official website at www.structuretx.com.

Structure Therapeutics Inc. American Depositary Shares

Nasdaq:GPCR

GPCR Rankings

GPCR Stock Data

1.88B
54.07M
4.84%
107.26%
18.26%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SOUTH SAN FRANCISCO